Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS1553 in R/R AML and Other Myeloid Neoplasms
NCT04637009Phase 1Terminated
- Sponsor
- Astex Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of TAS1553 in acute myeloid leukemia (AML), Myeloproliferative Neoplasm (MPN) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) (2 arms), sponsored by Astex Pharmaceuticals. Primary endpoints: Treatment-Emergent Adverse Events up to 12 months, Dose-Limiting Toxicities up to 12 months and 2 more. Started Dec 2020; status: terminated.
02
Drugs
TAS1553
03
Conditions
acute myeloid leukemia (AML)Myeloproliferative Neoplasm (MPN)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT04637009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04637009.